Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity.

摘要: Although the majority of patients with diffuse large B-cell lymphoma (DLBCL) can be cured standard rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP), who fail R-CHOP have a dismal outcome. Thus, optimization front-line therapy, as well development more effective salvage strategies, remains an important objective. Advances in molecular genetics vastly improved our understanding biological diversity DLBCL led to discovery key oncogenic pathways. In addition major designations germinal center activated subtypes, next-generation sequencing technologies unveiled remarkable complexity identified unique targets that may differentially exploited for therapeutic benefit. These findings translated into growing list promising novel agents. Moving forward, it is paramount importance recognize heterogeneity investigate these targeted agents within patient populations are most likely It will necessary prioritize drugs affect driver pathways combine them rationally optimize their Improved prognostication availability predictive biomarkers crucial allow possibility individualized risk-adapted therapy.